Background
==========

Community-acquired pneumonia (CAP) is routinely treated with antibiotic courses of 10--14 days. Procalcitonin (ProCT) is elevated in systemic bacterial infections, but remains low in viral infections. Its potential as a tool to guide AB prescription in lower respiratory tract infections has been shown \[[@B1]\]. This study aims to evaluate ProCT stewardship to reduce AB duration in patients with CAP.

Methods
=======

From a prospective, single-blinded, randomized study, data of 200 patients with CAP were analyzed. The standard group (*n*= 101) received antibiotics as generally recommended. In the ProCT group (*n*= 99), ProCT levels were measured at days 4, 6 and 8 and antibiotic therapy was discontinued if levels were \< 0.25 μg/l, measured with a sensitive assay (Kryptor PCT, BRAHMS, Germany). At baseline and at follow-up at 6 weeks, a standardized work-up was performed.

Results
=======

Baseline characteristics in both groups (Standard/ProCT) were similar (*P*values of quality of life score \[41 ± 22/43 ± 21\], temperature \[38 ± 1/38 ± 1\], leucocytes \[13 ± 6/14 ± 7\], C-reactive protein \[160 ± 95/142 ± 120\] and ProCT \[median: 0.4/0.6\] were not significant). Fifty-eight percent of patients had a high (class IV, V) pneumonia severity index. In the standard group, the mean duration of antibiotic therapy was 14.2 ± 7.3 days as compared with 6.2 ± 6.2 days in the ProCT group (*P*\< 0.001). A total 99.5% of patients underwent a follow-up. There were no differences in clinical, radiographic and laboratory outcome data as well as in mortality (14.5%) between groups.

Conclusions
===========

The duration of antibiotic treatment in patients with CAP can be markedly and safely reduced using a ProCT-guided treatment algorithm, with similar outcome. In view of the increasing antimicrobial resistance and costs, these findings have important clinical implications.
